{
    "eid": "2-s2.0-84975833688",
    "title": "Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: Results from the 2-year roadmap strategy",
    "cover-date": "2016-04-22",
    "subject-areas": [
        {
            "$": "Pharmacology",
            "@code": "3004"
        },
        {
            "$": "General Medicine",
            "@code": "2700"
        }
    ],
    "keywords": [
        "Chronic hepatitis B",
        "Glomerular filtration rate",
        "Hepatitis B e antigen",
        "Intensification",
        "Roadmap",
        "Telbivudine",
        "Tenofovir",
        "Virologic breakthrough"
    ],
    "authors": [
        "Teerha Piratvisuth"
    ],
    "citedby-count": 5,
    "ref-count": 23,
    "ref-list": [
        "WHO Fact Sheet on Hepatitis B",
        "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection",
        "Hepatitis B virus epidemiology, disease burden, treatment, arid current and emerging prevention and control measures",
        "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years-of therapy",
        "Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update",
        "Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B",
        "Chronic hepatitis B: Update 2009",
        "Hepatitis B: Modern End Points of Treatment and the Specter of Viral Resistance",
        "Telbivudine in the treatment of chronic hepatitis B",
        "Current and future antiviral drug therapies of hepatitis B chronic infection",
        "Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: A systematic review and meta-analysis",
        "Telbivudine versus lamivudine in patients with chronic hepatitis B",
        "Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B",
        "Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis",
        "Tenofovir: A nucleotide analog for the management of human immunodeficiency virus infection",
        "Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update",
        "52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B",
        "Hepatitis B and Renal Disease",
        "Telbivudine improves renal function in patients with chronic hepatitis b",
        "Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B",
        "Renal toxicity associated with tenofovir use",
        "Renal impairment in patients receiving a tenofovir-cART regimen: Impact of tenofovir trough concentration",
        "Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy"
    ],
    "affiliation": [
        {
            "affiliation-city": "Basel",
            "affilname": "Novartis International AG",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Sao Paulo",
            "affilname": "Universidade de S\u00e3o Paulo",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Rosario",
            "affilname": "Universidad Nacional de Rosario",
            "affiliation-country": "Argentina"
        },
        {
            "affiliation-city": "Hatyai",
            "affilname": "Faculty of Medicine, Prince of Songkla University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hannover",
            "affilname": "Hannover Medical School",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Khon Kaen",
            "affilname": "Khon Kaen University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Frankfurt am Main",
            "affilname": "Universit\u00e4tsklinikum Frankfurt",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Buenos Aires",
            "affilname": "Hospital de Cl\u00ednicas \"Jos\u00e9 de San Mart\u00edn\"",
            "affiliation-country": "Argentina"
        },
        {
            "affiliation-city": "Buenos Aires",
            "affilname": "Hospital Nacional Professor Dr. Alejandro Posadas",
            "affiliation-country": "Argentina"
        },
        {
            "affiliation-city": "Hong Kong",
            "affilname": "Chinese University of Hong Kong",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Bhaskara BP",
        "ICMJE",
        "Pravin Bolshete",
        "Bristol-Myers Squibb",
        "GlaxoSmithKline",
        "Merck",
        "Novartis",
        "Roche",
        "Gilead Sciences",
        "AbbVie",
        "Boehringer Ingelheim",
        "Janssen Pharmaceuticals"
    ]
}